Kyogo Itoh

Q: What Schools Are Affiliated With Kyogo Itoh

Kyogo Itoh is affiliated with the following schools: Tohoku University, MD Anderson Cancer Center, Kurume University

Kyogo Itoh's AcademicInfluence.com Rankings

Kyogo Itoh

Medical

#2836

World Rank

#3276

Historical Rank

Oncology

#184

World Rank

#190

Historical Rank

medical Degrees

Kyogo Itoh

Philosophy

#8128

World Rank

#11451

Historical Rank

Logic

#5159

World Rank

#6534

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Kyogo Itoh's Degrees

PhD Medical Science University of Tokyo
Doctorate Medicine University of Tokyo

Why Is Kyogo Itoh Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kyogo Itoh's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study (2018) (1224)
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours (2013) (1136)
Cancer classification using the Immunoscore: a worldwide task force (2012) (719)
Pretreatment of plastic Petri dishes with fetal calf serum. A simple method for macrophage isolation. (1979) (480)
Polymorphism of the 5′‐flanking region of the human tumor necrosis factor (TNF)‐α gene in Japanese (1998) (428)
Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor (1988) (342)
Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. (1985) (274)
Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. (1986) (270)
Studies on the bioperiodicity of the immune response. I. Circadian rhythms of human T, B, and K cell traffic in the peripheral blood. (1981) (259)
Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. (1990) (253)
Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. (1998) (239)
Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. (1995) (235)
Immunologic Aspects of the Nonobese Diabetic (NOD) Mouse: Abnormalities of Cellular Immunity (1983) (231)
A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes (1998) (227)
Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells. (1983) (188)
Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). (1985) (181)
Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. (1999) (166)
Suppressive effect of human natural killer cells on pokeweed mitogen-induced B cell differentiation. (1983) (160)
Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. (1998) (153)
Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. (2006) (150)
Studies of murine large granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities. (1982) (135)
Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma (2005) (132)
Identification of a Gene Coding for a New Squamous Cell Carcinoma Antigen Recognized by the CTL1 (2000) (130)
Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. (1987) (124)
Next‐generation peptide vaccines for advanced cancer (2013) (119)
Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses (2004) (119)
Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cells (1990) (115)
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination (2003) (113)
Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes. (1999) (113)
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. (2011) (111)
Immunopathological mechanisms of human T cell lymphotropic virus type 1 (HTLV-I) uveitis. Detection of HTLV-I-infected T cells in the eye and their constitutive cytokine production. (1995) (110)
Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. (2001) (110)
A second susceptibility gene for developing rheumatoid arthritis in the human MHC is localized within a 70-kb interval telomeric of the TNF genes in the HLA class III region. (2001) (103)
Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. (1996) (103)
Lysis of human solid tumor cells by lymphokine-activated natural killer cells. (1986) (103)
A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. (1999) (102)
Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin‐like protein, originally defined by the SEREX method (2002) (101)
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer (2010) (99)
Excision repair cross‐complementation group 1 predicts progression‐free and overall survival in non‐small cell lung cancer patients treated with platinum‐based chemotherapy (2007) (94)
A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma (2006) (93)
Personalized peptide vaccines: A new therapeutic modality for cancer (2006) (87)
New multiplexed flow cytometric assay to measure anti‐peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization (2004) (85)
Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. (1994) (83)
Studies of murine large granular lymphocytes. II. Tissue, strain, and age distributions of LGL and LAL. (1982) (80)
Tissue-specific distribution and age-dependent increase of human CD11b+ T cells. (1993) (79)
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. (2020) (79)
Molecular basis of T cell-mediated recognition of pancreatic cancer cells. (2001) (77)
Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine (2013) (77)
HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. (1995) (75)
A polymorphism of the 5′ flanking region of tumour necrosis factor α gene is associated with thyroid‐associated ophthalmopathy in Japanese (2000) (74)
Identification of a SART‐1‐derived peptide capable of inducing HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes (1999) (74)
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre‐existing cellular response to peptide (2003) (73)
Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases (2001) (72)
Recent advances in cancer vaccines: an overview. (2008) (72)
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. (2010) (70)
Vaccination with Predesignated or Evidence-Based Peptides for Patients with Recurrent Gynecologic Cancers (2004) (70)
A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation (2002) (70)
A case of chronic lymphocytic leukemia with properties characteristic of natural killer cells. (1983) (69)
Molecular cloning of a glycosylphosphatidylinositol-anchored molecule CDw108. (1999) (69)
Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection. (1996) (68)
Differential effect of interferon expression of IgG- and IgM-Fc receptors on human lymphocytes. (1980) (66)
Expression of the MAGE gene family in human head‐and‐neck squamous‐cell carcinomas (1995) (66)
Cytokine production by T cells infiltrating in the eye of uveitis patients. (1998) (66)
A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer. (2016) (64)
Immunological evaluation of CTL precursor‐oriented vaccines for advanced lung cancer patients (2003) (64)
Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells. (1985) (64)
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer (2014) (63)
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. (2009) (62)
A newly identified MAGE‐3‐derived epitope recognized by HLA‐A24‐restricted cytotoxic T lymphocytes (1999) (62)
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA‐A24+ HRPC patients (2005) (60)
Strong association of a tumor necrosis factor-α promoter allele with cerebral malaria in Myanmar (2001) (59)
Dominant Infiltration of TH 1-type CD4+ T Cells at the Retrobulbar Space of Patients with Thyroid-Associated Ophthalmopathy (1999) (59)
Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer (2007) (58)
Expression of MAGE genes in osteosarcoma (1997) (58)
Characterization of autologous tumor‐specific T‐helper 2 cells in tumor‐infiltrating lymphocytes from a patient with metastatic melanoma (1994) (57)
A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer (2016) (57)
Expression of the tumor‐rejection antigen SART1 in brain tumors (1999) (56)
Identification of SART3‐derived peptides capable of inducing HLA‐A2‐restricted and tumor‐specific CTLs in cancer patients with different HLA‐A2 subtypes (2000) (56)
Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. (2000) (55)
HLA class‐I‐restricted and tumor‐specific CTL in tumor‐infiltrating lymphocytes of patients with gastric cancer (1997) (54)
Expression of the SART3 Tumor-Rejection Antigen in Brain Tumors and Induction of Cytotoxic T Lymphocytes by Its Peptides (2000) (53)
Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis (2000) (53)
Expression of MAGE‐1, MAGE‐2, MAGE‐3/‐6 and MAGE‐4A/‐4B genes in ovarian tumors (1995) (50)
Prostate‐specific antigen‐derived epitopes capable of inducing cellular and humoral responses in HLA‐A24+ prostate cancer patients (2003) (50)
Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy. (2004) (50)
Detection of mage‐4 protein in lung cancers (1995) (50)
Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. (2007) (50)
Ran, a Small GTPase Gene, Encodes Cytotoxic T Lymphocyte (CTL) Epitopes Capable of Inducing HLA-A33–restricted and Tumor-Reactive CTLs in Cancer Patients (2004) (50)
Immunological evaluation of personalized peptide vaccination in combination with a 5‐fluorouracil derivative (TS‐1) for advanced gastric or colorectal carcinoma patients (2007) (50)
Regional growth of different human melanomas as metastases in the brain of nude mice. (1990) (49)
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients (2004) (49)
Spontaneous production of various cytokines except IL‐4 from CD4+ T cells in the affected organs of sarcoidosis patients (1995) (49)
Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. (2001) (49)
Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the Periphery (2003) (47)
A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma (2018) (47)
Phase I clinical study of a peptide vaccination for hepatitis C virus‐infected patients with different human leukocyte antigen‐class I‐A alleles (2009) (47)
Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer (2014) (47)
Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer (2007) (47)
A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. (2000) (47)
Locoregional cellular immunotherapy for patients with advanced esophageal cancer. (2000) (46)
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. (2013) (45)
Polymorphisms in the 5'-flanking region of tumor necrosis factor-alpha gene in patients with rheumatoid arthritis. (1999) (44)
Malignant potential of cells isolated from lymph node or brain metastases of melanoma patients and implications for prognosis. (1991) (44)
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. (2012) (44)
Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. (2001) (44)
Phase II study of personalized peptide vaccination for castration‐resistant prostate cancer patients who failed in docetaxel‐based chemotherapy (2012) (43)
Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer (2004) (43)
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients (2009) (43)
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy (2015) (43)
Personalized peptide vaccine for treatment of advanced cancer. (2014) (42)
Phase I trial of patient‐oriented vaccination in HLA‐A2‐positive patients with metastatic hormone‐refractory prostate cancer (2004) (42)
Phase I trial of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patients (2007) (42)
CDw108 expression during T-cell development. (2000) (41)
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination (2010) (41)
Identification of Lck‐derived peptides capable of inducing HLA‐A2‐restricted and tumor‐specific CTLs in cancer patients with distant metastases (2001) (41)
Prostatic Acid Phosphatase as a Target Molecule in Specific Immunotherapy for Patients With Nonprostate Adenocarcinoma (2005) (41)
Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine. (2015) (40)
Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients (2013) (40)
Effectiveness of glycyrrhizin for oral lichen planus in patients with chronic HCV infection (1996) (39)
Personalized peptide vaccination in patients with refractory non-small cell lung cancer. (2012) (39)
Predictive factors of the tumor immunological microenvironment for long‐term follow‐up in early stage breast cancer (2017) (39)
Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. (2003) (39)
Identification of Peptide Vaccine Candidates Sharing among HLA-A3+, -A11+, -A31+, and -A33+ Cancer Patients (2004) (39)
A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese. (2000) (38)
Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination (2012) (38)
Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa. (2004) (38)
γ/δ T cell antigen receptors expressed on tumor‐infiltrating lymphocytes from patients with solid tumors (1992) (38)
Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma (2019) (38)
A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low‐dose estramustine in HLA‐A24‐positive patients with castration‐resistant prostate cancer (2011) (38)
Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. (2006) (38)
Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms. (2008) (37)
Human tumor rejection antigens MAGE. (1996) (37)
Analysis of tumor necrosis factor-alpha promoter polymorphism in type 1 diabetes: HLA-B and -DRB1 alleles are primarily associated with the disease in Japanese. (2000) (37)
Analysis of tumor necrosis factor‐α production and polymorphisms of the tumor necrosis factor‐α gene in individuals with a history of Kawasaki disease (1999) (37)
Polymorphism of the 5'-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis. (1999) (36)
Identification of a prostate‐specific membrane antigen‐derived peptide capable of eliciting both cellular and humoral immune responses in HLA‐A24+ prostate cancer patients (2003) (36)
Induction of MAGE Genes in Lymphoid Cells by the Demethylating Agent 5‐Aza‐2′‐deoxycytidine (1996) (36)
Inhibition of natural killer cell activity by IgA. (1986) (35)
Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma. (1990) (34)
Strong association of a tumor necrosis factor-alpha promoter allele with cerebral malaria in Myanmar. (2001) (34)
Two Proliferation-Related Proteins, TYMS and PGK1, Could Be New Cytotoxic T Lymphocyte-Directed Tumor-Associated Antigens of HLA-A2+ Colon Cancer (2004) (34)
Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. (2010) (34)
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients (2014) (34)
Identification of Peptide Vaccine Candidates for Prostate Cancer Patients with HLA-A3 Supertype Alleles (2005) (34)
Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. (2002) (33)
Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles (2007) (32)
Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes. (2001) (32)
Susceptible locus for obese type 2 diabetes mellitus in the 5'-flanking region of the tumor necrosis factor-alpha gene. (2000) (32)
Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. (1985) (32)
Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)‐derived peptides immunogenic in HLA‐A24+ prostate cancer patients (2004) (32)
Immunological monitoring during combination of patient‐oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer (2004) (31)
Phase 1 Clinical Study of Cyclophilin B Peptide Vaccine for Patients With Lung Cancer (2002) (31)
Expression of tumor rejection antigens in colorectal carcinomas (2002) (31)
Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. (1998) (30)
Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. (2010) (30)
Expression of the SART3 tumor rejection antigen in renal cell carcinoma. (2000) (30)
Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer. (2005) (30)
Binding of a SART3 tumor‐rejection antigen to a pre‐mRNA splicing factor RNPS1: A possible regulation of splicing by a complex formation (2001) (30)
Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes. (1988) (29)
Dissection and identification of regions required to form pseudoparticles by the interaction between the nucleocapsid (N) and membrane (M) proteins of SARS coronavirus (2008) (29)
Target molecules in specific immunotherapy against prostate cancer (2003) (29)
Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients (2003) (29)
Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone‐releasing hormone agonist versus flutamide plus luteinizing hormone‐releasing hormone agonist (2004) (29)
Identification of Cyclophilin B‐derived Peptides Capable of Inducing Histocompatibility Leukocyte Antigen‐A2‐restricted and Tumor‐specific Cytotoxic T Lymphocytes (2001) (28)
Subpopulation analysis of human granular lymphocytes: associations with age, gender and cytotoxic activity. (1986) (28)
Expression of the SART‐1 tumor rejection antigen in breast cancer (1999) (28)
Identification of a second T-cell antigen receptor in human and mouse by an anti-peptide gamma-chain-specific monoclonal antibody. (1987) (28)
Genetic factors associated with serum haptoglobin level in a Japanese population. (2014) (28)
Detection of peptide‐specific cytotoxic T‐lymphocyte precursors used for specific immunotherapy of pancreatic cancer (2002) (28)
Dominant infiltration of T(H)1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy. (1999) (28)
Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors. (2002) (27)
Changes in NK cell activity during the estrous cycle and pregnancy in mice. (1984) (27)
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer (2017) (27)
In Vitro Cytotoxic Activity of Interleukin 2‐Dependent Murine Thy‐1+ Dendritic Epidermal Cell Lines (1988) (27)
Expression of a newly defined tumor‐rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I‐restricted cytotoxic T lymphocytes by SART3‐derived peptides (2001) (27)
TCR gamma delta + T cells in peripheral blood of patients with adult Still's disease. (1996) (26)
A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin (2011) (26)
UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour (2002) (26)
Effect of tunicamycin and neuraminidase on the expression of Fc-IgM and -IgG receptors on human lymphocytes. (1980) (26)
Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. (2007) (25)
Study of Tumor-Infiltrating Lymphocytes for Adoptive Therapy of Renal Cell Carcinoma (RCC) and Metastatic Melanoma: Sequential Proliferation of Cytotoxic Natural Killer and Noncytotoxic T Cells in RCC (1991) (25)
A prostate stem cell antigen‐derived peptide immunogenic in HLA‐A24− prostate cancer patients (2004) (25)
Expression of the MAGE gene family in human lymphocytic leukemia. (1995) (25)
High expression of APOBEC3G in patients infected with hepatitis C virus (2006) (24)
Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. (2004) (24)
ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients. (2005) (23)
IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients. (2003) (23)
Selective growth of human melanoma cells in the brain parenchyma of nude mice (1996) (23)
Expression of MAGE‐1 Gene by Esophageal Carcinomas (1995) (23)
Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients (2014) (23)
DAB486IL‐2 (IL‐2 Toxin) Selectively Inactivates High‐Affinity IL‐2 Receptor‐Bearing Human Peripheral Blood Mononuclear Cells (1991) (22)
Sequence analysis of the MAGE gene family encoding human tumor-rejection antigens. (1995) (22)
Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer (2012) (22)
Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer (1999) (22)
Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients (2004) (22)
Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer (2012) (22)
Suppression by IL-10 and IL-4 of cytokine production induced by two-way autologous mixed lymphocyte reaction. (1996) (22)
HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. (2007) (21)
Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. (2004) (21)
Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432. (2006) (21)
Detection of MAGE‐4 protein in sera of patients with head‐and‐neck squamous‐cell carcinoma (1997) (20)
Measurement of interferon-γ by high-throughput fluorometric microvolume assay technology system (2002) (20)
Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients. (2004) (20)
The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone. (1991) (20)
Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles (2007) (19)
Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients (2002) (19)
Expression of the SART1 tumor-rejection antigen in human osteosarcomas. (2000) (19)
Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients (2001) (19)
Human tumor-infiltrating lymphocytes (1993) (19)
Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression (2015) (19)
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time (2013) (19)
Vaccination of Cytotoxic T Lymphocyte-Directed Peptides Elicited and Spread Humoral and Th1-Type Immune Responses to Prostate-Specific Antigen Protein in a Prostate Cancer Patient (2005) (19)
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer. (1997) (19)
Production of IL‐6 by T cells from the femoral head of patients with rapidly destructive coxopathy (RDC) (1996) (18)
Beta 2-integrin-mediated signal up-regulates counterreceptor ICAM-1 expression on human monocytic cell line THP-1 through tyrosine phosphorylation. (1997) (18)
Immunotherapy in prostate cancer: challenges and opportunities. (2016) (18)
In Vitro Effects of Immunosuppressive Agents on Cytokine Production by HTLV‐I‐Infected T Cell Clones Derived from the Ocular Fluid of Patients with HTLV‐I Uveitis (1996) (18)
Expression of the SART1 tumor-rejection antigens in colorectal cancers (2000) (18)
Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients (2008) (18)
HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients. (2004) (18)
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma. (1997) (18)
Expression of SART3 Tumor‐rejection Antigen in Gastric Cancers (2000) (18)
Evaluation of a new oil adjuvant for use in peptide‐based cancer vaccination (2010) (18)
Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients (2004) (18)
Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes. (1989) (18)
Histocompatibility Leukocyte Antigen‐A2402‐restricted Cytotoxic T Lymphocytes Recognizing Adenocarcinoma in Tumor‐infiltrating Lymphocytes of Patients with Colon Cancer (1997) (17)
Molecular heterogeneity of gamma delta T-cell antigen receptors expressed by CD4- CD8- T-cell clones from normal donors: both disulfide- and non-disulfide-linked receptors are delta TCS1+. (1989) (17)
Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration‐resistant prostate cancer (2010) (17)
High prevalence of hepatitis C virus antibody and RNA in patients with head and neck squamous cell carcinoma (1997) (17)
Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha. (1991) (16)
New Peptide Vaccine Candidates for Epithelial Cancer Patients With HLA-A3 Supertype Alleles (2007) (16)
Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. (2006) (16)
Spontaneous human T-cell cytotoxicity against murine hybridomas expressing the OKT3 monoclonal antibody: comparison with natural killer cell activity. (1987) (16)
Characterization of CD4+ T helper cells in patients with Kawasaki disease (KD): preferential production of tumour necrosis factor-alpha (TNF-alpha) by V beta 2- or V beta 8- CD4+ T helper cells. (1995) (16)
Human renal‐cell carcinoma cells are able to activate natural killer cells (1992) (16)
Establishment of an enzyme-linked immunosorbent assay (ELISA) for measuring cellular MAGE-4 protein on human cancers. (1995) (16)
Growth and metastatic behavior of human tumor cells implanted into nude and beige nude mice (1987) (15)
Cleavage and polyadenylation specificity factor (CPSF)‐derived peptides can induce HLA‐A2‐restricted and tumor‐specific CTLs in the majority of gastrointestinal cancer patients (2002) (15)
Distribution of autologous tumor‐specific cytotoxic T lymphocytes in human metastatic melanoma (1992) (15)
Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients (2015) (15)
Expression of Tumor‐rejection Antigens in Gynecologic Cancers (2000) (15)
Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses. (1986) (15)
In Vivo Evidence That Peptide Vaccination Can Induce HLA-DR-Restricted CD4+ T Cells Reactive to a Class I Tumor Peptide 1 (2004) (15)
Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer (2017) (15)
EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation (2013) (15)
Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine (2017) (15)
Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. (2008) (15)
Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). (1993) (15)
Expression of the SART1 tumor rejection antigen in renal cell carcinoma (2000) (15)
Peptide-based immunotherapeutic approaches to glioma: a review (2007) (15)
Cell cycle arrest and apoptosis induced by SART-1 gene transduction. (2005) (15)
Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. (2004) (14)
T‐cell receptor Vβ gene usage by T cells reactive with the tumor‐rejection antigen SART‐1 in oral squamous cell carcinoma (2004) (14)
HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers. (1997) (14)
New epitope peptides derived from parathyroid hormone‐related protein which have the capacity to induce prostate cancer‐reactive cytotoxic T lymphocytes in HLA‐A2+ prostate cancer patients (2005) (14)
Erythropoietin‐producing hepatocyte B6 variant‐derived peptides with the ability to induce glioma‐reactive cytotoxic T lymphocytes in human leukocyte antigen‐A2+ glioma patients (2008) (14)
Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes. (2003) (14)
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial (2020) (14)
Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer (2016) (14)
Identification of target antigens in specific immunotherapy for renal cell carcinoma. (2007) (14)
Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells. (1987) (14)
Production of IL-8 and the other cytokines by T cell clones established from the ocular fluid of patients with Behçet's disease. (1995) (14)
A unique gene having homology with the kinesin family member 18A encodes a tumour-associated antigen recognised by cytotoxic T lymphocytes from HLA-A2+ colon cancer patients. (2005) (13)
Lysis of fresh solid tumor targets in the presence of Con A is mediated primarily by Leu 7+ peripheral blood T lymphocytes: blocking by the anti-CD3 monoclonal antibody and comparison with recombinant interleukin 2-induced lysis by natural killer cells. (1987) (13)
Gamma/delta T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors. (1992) (13)
Current status of immunotherapy for the treatment of biliary tract cancer (2013) (13)
Antibody Reactive to a Hepatitis C Virus (HCV)‐Derived Peptide Capable of Inducing HLA‐A2 Restricted Cytotoxic T Lymphocytes Is Detectable in a Majority of HCV‐Infected Individuals without HLA‐A2 Restriction (2004) (13)
Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. (2009) (13)
Prospect and progress of personalized peptide vaccinations for advanced cancers (2016) (13)
Serum MAGE-4 protein in ovarian cancer patients. (2000) (13)
Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity (2004) (13)
Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. (2013) (13)
Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL. (2003) (13)
Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients. (2007) (12)
Detection of Circulating Tumor Cells in Patients with Prostate Cancer Using Prostate Specific Membrane‐Derived Primers in the Polymerase Chain Reaction (1997) (12)
Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma (2017) (12)
A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33 (2007) (12)
Parathyroid hormone-related protein as a common target molecule in specific immunotherapy for a wide variety of tumor types. (2005) (12)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
Analysis of cellular localization of SART3 tumor antigen by a newly established monoclonal antibody: heterotopic expression of SART3 on the surface of B-lineage leukemic cells. (2004) (11)
Expression of APOBEC3G in kidney cells. (2007) (11)
Detection of MAGE‐4 Protein in the Sera of Patients with Hepatitis‐C Virus‐associated Hepatocellular Carcinoma and Liver Cirrhosis (1997) (11)
An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles (2009) (11)
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. (2010) (11)
Polyclonal use of T-cell receptor alpha for human T-cell lymphotropic virus type 1-infected T cells. (1995) (11)
Identification of HER2/neu-Derived Peptides Capable of Inducing both Cellular and Humoral Immune Responses in HLA-A24 Positive Breast Cancer Patients (2004) (11)
Monocyte-independent interleukin-2 production and proliferation of human T cells in response to murine hybridomas expressing the OKT3 monoclonal antibody: interleukin-1 is not required for T-cell proliferation. (1988) (11)
Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients (2016) (11)
HLA-A2402-Restricted and Tumor-Specific Cytotoxic T Lymphocytes from Tumor-Infiltrating Lymphocytes of a Child with Wilms' Tumor (1997) (10)
Haptoglobin Proved a Prognostic Biomarker in Peripheral Blood of Patients with Personalized Peptide Vaccinations for Advanced Castration-Resistant Prostate Cancer (2013) (10)
Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides (2012) (10)
A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles (2009) (10)
Effector cell analysis of tumor cell rejection in vivo in two syngeneic tumor systems exhibiting distinct in vitro cytotoxic mechanisms. (1984) (10)
Identification of two novel tumor-associated antigens recognized by HLA-B46-restricted cytotoxic T lymphocytes. (2003) (10)
Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer (2020) (10)
Development of a new diagnostic tool for pancreatic cancer: simultaneous measurement of antibodies against peptides recognized by cytotoxic T lymphocytes. (2006) (10)
Mouse Homologue of the Human SART3 Gene Encoding Tumor‐rejection Antigen (2000) (10)
Detection of guinea pig Tμ and Tγ cells by a double rosette assay (1982) (9)
Nonmutated Self-Antigen-Derived Cancer Vaccine Peptides Elicit an IgE-Independent but Mast Cell-Dependent Immediate-Type Skin Reaction without Systemic Anaphylaxis1 (2006) (9)
Polyclonal uses of T‐cell receptor (TCR)α and β genes for cytotoxic T lymphocytes in human metastatic melanoma: possible involvement of TCRα in tumor‐cell recognition (1994) (9)
A monoclonal antibody (H227) recognizing a new epitope of 4F2 molecular complex associated with T cell activation. (1993) (9)
Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center (1989) (9)
[Specific immunotherapy with cancer vaccines]. (2000) (9)
A novel antigen (H47 Ag) on human lymphocytes involved in T cell activation. (1993) (9)
Expression of the SART‐1 Antigens in Uterine Cancers (1998) (9)
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens. (2015) (9)
Recent advances in active specific cancer vaccine treatment for colorectal cancer. (2012) (9)
Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine (2013) (8)
Clinical development of immunotherapy for prostate cancer (2017) (8)
Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients (2015) (8)
Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy (2015) (8)
Detection of a set of peptide vaccine candidates for use in HLA-A31+ epithelial cancer patients. (2004) (8)
PHASE I TRIAL OF MURINE ANTI-GANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (Mab) 14G2A IN CANCER PATIENTS (1992) (8)
Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer (2017) (8)
A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel (2020) (8)
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers (2018) (8)
Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein. (2013) (8)
Reduced expression of erythropoietin-producing hepatocyte B6 receptor tyrosine kinase in prostate cancer (2015) (8)
T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma. (2004) (7)
Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer. (2007) (7)
T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma. (1992) (7)
Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients (1989) (7)
Personalized peptide vaccination for advanced colorectal cancer (2015) (7)
Detection of MAGE‐4 Protein in Sera of Lung Cancer Patients (1997) (7)
Development of cancer vaccine by tumor rejection antigens. (1997) (7)
Expression of theMAGE gene family in human lymphocytic leukemia (2005) (7)
Identification of a CTL‐directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA‐B52+ and HLA‐62+ cancer patients (2003) (6)
Measurement of interferon-gamma by high-throughput fluorometric microvolume assay technology system. (2002) (6)
Oligoclonal expansion of Vβ8+ cells in interleukin-2-activated T cells residing in subcutaneous metastatic melanoma (2004) (6)
Serine Proteinase Inhibitor 9 Can Be Recognized by Cytotoxic T Lymphocytes of Epithelial Cancer Patients (2002) (6)
Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients. (2006) (6)
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele (2015) (5)
Identification of hepatitis C virus 1b-derived peptides recognized by both cellular and humoral immune systems in HCV1b(+) HLA-A24(+) patients. (2005) (5)
Immunological consequences following splenectomy in patients with liver cirrhosis. (2019) (5)
Controversies in Clinical Trials of Cancer Vaccines for Glioblastoma (2012) (5)
Tumor Immunotherapy of Esophageal and Gastric Cancers (2015) (5)
Identification of peptides applicable as vaccines for HLA‐A26‐positive cancer patients (2009) (5)
Immunological evaluation of vaccination of peptides derived from epithelial cancer-related antigens in two patients with hematological malignancy. (2005) (5)
Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas. (2001) (5)
Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib (2014) (5)
Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer. (2005) (5)
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies (2017) (5)
HLA-B35 and MICA-A5 synergistically enhanced the susceptibility to Chagas heart disease (2000) (5)
Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase (2018) (5)
[A phase I study of combination-therapy using personalized peptide vaccine and UFT/UZEL for advanced or recurrent colorectal cancer]. (2006) (5)
Humoral modulation of lymphokine‐activated killer (LAK)‐cell induction in humans: IgG‐related and non‐IgG inhibitors in sera from cancer patients (1990) (4)
Sequence Analysis of Genes Encoding Rodent Homologues of the Human Tumor‐rejection Antigen SART‐1 (1998) (4)
Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients. (2006) (4)
Depressed natural killer activity in rheumatoid arthritis and its in vitro augmentation with interferon and N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt (CCA), an anti-arthritis agent. (1981) (4)
New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients. (2007) (4)
Induction of Human Leukocyte Antigen-A26–Restricted and Tumor-Specific Cytotoxic T Lymphocytes by a Single Peptide of the SART1 Antigen in Patients With Cancer With Different A26 Subtypes (2000) (4)
Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females. (2017) (4)
Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients. (2006) (4)
Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. (2011) (4)
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. (1991) (4)
New Epitope Peptides Derived from Hepatitis C Virus (HCV) 2a Which Have the Capacity to Induce Cytotoxic T Lymphocytes in HLA‐A2+ HCV‐Infected Patients (2006) (4)
Identification of novel Lck‐derived T helper epitope long peptides applicable for HLA‐A2+ cancer patients as cancer vaccine (2015) (4)
New type of natural antibodies reactive to cytotoxic T lymphocyte-directed cancer vaccine peptides. (2004) (4)
CD8+ T cells lyse autologous monocytes in the presence of anti-CD3 monoclonal antibody: association with interleukin-1 production. (1988) (4)
Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11+ or ‐A33+ allele (2017) (4)
Cytokines Required for Induction of Histocompatibility Leukocyte Antigen‐class I‐restricted and Tumor‐specific Cytotoxic T Lymphocytes by a SART1‐derived Peptide (1999) (4)
Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b+ HLA‐A24+ patients (2007) (3)
Capability of SART 3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A 11 ,-A 31 andA 33 alleles (3)
Effects of HC antibody in autologous tumor‐specific cytotoxicity by human melanoma tumor‐infiltrating lymphocytes (1991) (3)
Disulfide-linked and non-disulfide-linked gamma/delta T-cell antigen receptors: differential expression on T-cell lines and clones derived from normal donors and patients with primary immunodeficiency disorders. (1992) (3)
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy (1991) (3)
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center. (1989) (3)
Determination of Thrombopoietin‐Derived Peptides Recognized by Both Cellular and Humoral Immunities in Healthy Donors and Patients with Thrombocytopenia (2005) (3)
Increase in the capability of interleukin 2 gene-transduced renal cell carcinoma cells to induce cytotoxic lymphocytes. (1994) (3)
Expression of Epithelial Cancer-Related Antigens in Hematologic Malignancies Applicable for Peptide-Based Immunotherapy (2004) (3)
[Tumor-rejection antigens expressed on human squamous cell carcinoma]. (1995) (2)
Changes in the mononuclear cell subpopulations of rat cardiac transplant recipients administered FK506 for the treatment of ongoing rejection (1995) (2)
Personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel: A randomized, double-blind, placebo-controlled, phase III trial (2020) (2)
Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination (2015) (2)
Serum levels of IgG to the peptide of HCV1b core at positions 35–44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132–2140 correlated with better prognosis in HCV-infected patients (2007) (2)
Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen ( HLA-A 2 ,-A 3 ,-A 11 ,-A 24 ,-A 31 andA 33 )-positive patients with advanced cancer (2)
In vitro induction of specific CD8+ T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma. (2012) (2)
Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients (2020) (2)
Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer (2016) (2)
Feasibility study of multiple HLA-class IA restricted peptide vaccines (KRM-19) for metastatic triple negative breast cancer (TNBC). (2017) (2)
Personalized immunotherapy in colorectal cancer (2016) (2)
Elevation of Serum MAGE‐4 Protein Levels and Prediction of Hepatocellular Carcinogenesis in Patients with Liver Cirrhosis (2002) (2)
Role of uncultured human melanoma cells in the proliferation of autologous tumor-specific cytotoxic T lymphocytes. (1992) (2)
601 A PHASE I STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR ADVANCED UROTHELIAL CARCINOMA PATIENTS WHO FAILED TREATMENT WITH METHOTREXATE, VINBLASTINE, ADRIAMYCIN AND CISPLATIN (2011) (2)
P07.02 Trials of a personalized peptide vaccine (ITK-1) for patients with recurrent or progressive glioblastoma (GBM). (2017) (2)
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients with hormone-refractory prostate cancer. (2009) (2)
A multicenter phase I/II study of gemcitabine and personalized peptide vaccination combination therapy for metastatic pancreatic cancer patients (2008) (2)
SY1. building the foundation for investigator-initiated clinical trial (2012) (2)
Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site (2016) (2)
Non-restricted T cell receptor (TCR)-V alpha and -V beta gene usage in patients with pulmonary sarcoidosis. (1997) (2)
A monoclonal antibody KIS‐1 recognizing a new membrane antigen on human squamous‐cell carcinoma (1996) (2)
Personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo-controlled, phase III trial. (2019) (2)
Aberrant Expression of p56lck in Primary Oral Cancer (2007) (1)
Molecular heterogeneity of y6 T-cell antigen receptors expressed by CD4- CD8- T-cell clones from normal donors: Both disulfide-and non-disulfide-linked receptors are 6TCS1I (1)
Randomized phase II study of personalized peptide vaccination with cyclophosphamide pretreatment in refractory advanced biliary tract cancer patients. (2014) (1)
Randomized phase II study of personalized peptide vaccination in patients with advanced bladder cancer progressing after chemotherapy. (2014) (1)
Induction of specific anti-tumor responses by CA9 peptide vaccination in patients with metastatic renal cell carcinoma (2006) (1)
[Personalized peptide vaccination]. (2012) (1)
A correlation between symptom severity and unbalanced reactive IgA production in Japanese cedar pollinosis patients. (2008) (1)
Lymphokine production by human melanoma tumor-infiltrating lymphocytes (2005) (1)
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer (2013) (1)
Abstract P5-01-05: Personalized peptide vaccines in combination with conventional chemo- or endocrine therapy for metastatic breast cancer: A single-arm phase II study (2013) (1)
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients previously treated with two or more chemotherapy regimens. (2014) (1)
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients (2014) (1)
Phase II study of personalized peptide vaccine for refractory breast cancer patients. (2012) (1)
A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients. (2010) (1)
Prophylactic effect of peptide vaccination against hepatocellular carcinoma associated with hepatitis C virus (2010) (1)
[Development of Peptide Vaccines for Triple-Negative Breast Cancer Treatment]. (2016) (1)
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time (2013) (1)
POS-02.75: A randomized clinical trial of an ethanol extract of Ganoderma lucidum (edible and medicinal mushroom) in men with lower urinary tract symptoms (2007) (1)
High Prevalence of Claudin 18.2 Expression in Japanese Patients with Gastric Cancer. (2017) (1)
Phase I/II study of individualized peptide vaccines for HLA-A2/A24 positive patients with hormone-refractory prostate cancer (2008) (1)
[Human tumor-rejection antigens and peptides from genes to clinical research]. (2000) (1)
Immunological evaluation of personalized peptide vaccination with gemcitabine for advance pancreatic cancer patients. (2006) (1)
[Peptide vaccination therapy for malignant glioma]. (2007) (1)
[Tumor-infiltrating lymphocytes from human metastatic melanoma]. (1987) (1)
Peptide vaccines with low-dose dexamethasone versus dexamethasone alone for chemotherapy-naive castration resistant prostate cancer: A randomized phase II study. (2014) (1)
Safety and immunologic efficacy of personalized multiple HLA class I-restricted peptide vaccines for breast cancer patients in the adjuvant setting. (2014) (1)
Immunological evaluation of personalized peptide vaccination for metastatic breast cancer patients with triple-negative types. (2012) (1)
Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine (2019) (1)
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: A randomized, double-blind, placebo-controlled, phase 2 trial. (2018) (1)
Cancer classification using the Immunoscore: a worldwide task force (2012) (1)
Monocyte independent il 2 production and proliferation of human t cells in response to murine hybridomas expressing the okt3 monoclonal antibody mab (1987) (0)
Exploring immune therapy for renal cancer. (2011) (0)
Augmentation of K-cell activity by human interferon (1982) (0)
Abstract P3-05-09: Prognostic factors for therapeutic personalized peptide vaccines in patients with metastatic recurrent breast cancer (2018) (0)
The Clinical Role of Peptide Vaccines for Castration-Resistant Prostate Cancer (2012) (0)
[HLA-restricted cancer-specific killer T cells]. (2005) (0)
967 IMMUNOLOGICAL EVALUATION OF PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH CYTOKINE REFRACTORY ADVANCED RENAL CELL CANCER (2007) (0)
[Current status and future perspective of cancer vaccine development]. (2011) (0)
Tumor-Specific CTLs Epitopes Recognized by HLA-A 24-Restricted A Cyclophilin B Gene Encodes Antigenic (1999) (0)
863 Phase II study of personalized peptide vaccination for standard therapy-resistant urothelial carcinoma patients (2012) (0)
OR128 CTL AND IGG RESPONSE TO TUMOR-ASSOCIATED ANTIGENS AS PREDICTIVE FACTORS OF THERAPEUTIC PEPTIDE VACCINATION FOR PATIENTS WITH METASTATIC RECURRENT BREAST CANCER (2015) (0)
98 Combination therapy of peptide vaccines and dexamethasone for chemotherapy naïve castration resistant prostate cancer – a randomized phase-2 study (2013) (0)
Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation (1993) (0)
IL‐2‐Dependent Murine T‐Cell Lines and Clones Expressing Gamma/Delta T‐Cell Antigen Receptors. I, Functional and Biochemical Characterization (1991) (0)
Personalised Peptide Vaccination for Castration-Resistant Prostate Cancer Progressing after Docetaxel Chemotherapy: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (2019) (0)
Abstract P5-08-16: Local immunologic environment related with tumor infiltrating lymphocytes (TIL) and PD-1/PD-L1 expression in early stage breast cancer (2016) (0)
Polyclonal uses of T-cell receptor (TCR)alpha and beta genes for cytotoxic T lymphocytes in human metastatic melanoma: possible involvement of TCR alpha in tumor-cell recognition. (1994) (0)
Abstract 760: Gene expression profiling in cancer vaccine: A new tool for cancer vaccine development (2011) (0)
[Identification and characterization of effector lymphocytes lysing autologous tumor cells]. (1989) (0)
[Acquired tumor "robustness" in the case of prostate cancer]. (2006) (0)
Phase I trial of personalized peptide vaccine for HLA-A24 positive patients with advanced cancer (2008) (0)
Abstract P2-11-04: Serum IgG response against prostate-related antigen revealed by personalized peptide vaccination in patients with metastatic recurrent breast cancer (2016) (0)
Abstract LB-134: Personalized peptide vaccination as the second line therapy for patients with chemotherapy-resistant advanced pancreatic cancer. (2012) (0)
Detection of IgE antibody specific to a hepatitis C virus-derived peptide being recognized by cellular immunity in patients with HCV infection. (2008) (0)
611 Immunological evaluation of individualized peptide vaccination with low dose of estramustine for HRPC patients (2004) (0)
Randomized phase II study of docetaxel plus personalized peptide vaccination versus docetaxel plus placebo for patients previously treated for advanced wild-type EGFR non-small-cell lung cancer. (2015) (0)
Single nucleotide polymorphisms of the haptoglobin gene in non-small cell lung cancer treated with personalized peptide vaccination. (2017) (0)
Tumor-specific t cell activation by peptide antigens (2001) (0)
Cells Reactive to a Class I Tumor Peptide T + Can Induce HLA-DR-Restricted CD4 In Vivo Evidence That Peptide Vaccination (2004) (0)
T lymphocytes with receptors for IgM-Fc (T mu) as an effector cell in delayed-type hypersensitivity. (1982) (0)
Distinct Characterstics of IgM-Fc and IgG-Fc Receptors in Nature, Expression and Modulation (1982) (0)
674 DELAYED PSA RESPONSES IN PERSONALIZED PEPTIDE VACCINATION FOR CASTRATE-RESISTANT PROSTATE CANCER PATIENTS PHASE II STUDY (2012) (0)
UP-02.36: Immune response and anti-tumor activity of preoperative peptide vaccination for patients with localized prostate cancer (2006) (0)
Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines (2021) (0)
PHASE II STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR METASTATIC UPPER TRACT UROTHELIAL CANCER PATIENTS REFRACTORY TO THE STANDARD CHEMOTHERAPY: MP78‐06 (2017) (0)
[Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2]. (1993) (0)
Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination (2013) (0)
[Current status and prospects of cancer vaccine therapy]. (2011) (0)
Evaluation of immunological efficacy of Japanese herbal medicine, hochu-ekki-to and keishi-bukuryo-gan, in patients with castration-resistant prostate cancer under personalized peptide vaccination. (2017) (0)
PHASE-1 STUDY OF CARBONIC ANHYDRASE 9 PEPTIDE VACCINES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (2006) (0)
Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe (2016) (0)
A phase II study of personalized selection of peptide vaccines combined with conventional chemo- or endocrine therapy for refractory breast cancer. (2010) (0)
Evaluation of the immunological response of patients with childhood cancer treated with the personalized peptide vaccine for refractory soft tissue sarcoma: An early phase II study (2020) (0)
Skin Reaction without Systemic Anaphylaxis but Mast Cell-Dependent Immediate-Type Vaccine Peptides Elicit an IgE-Independent Nonmutated Self-Antigen-Derived Cancer (2005) (0)
Interleukin-2-Induced Differentiation of Natural Killer Cells to Activated Killer Cells (1986) (0)
T-Lymphocyte Response in Renal Cell Carcinoma (1995) (0)
Toll-like receptors (PP-001) (2010) (0)
P2.04-65 Peptide-Based Cancer Vaccine Shortened the Overall Survival of a Large Portion, but Not All, of Advanced Cancer Patients (2019) (0)
Personalized Peptide Vaccine for Advanced Pancreatic Cancer (2017) (0)
520 PHASE II STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR CISPLATIN-BASED CHEMOTHERAPY RESISTANT ADVANCED UROTHELIAL CARCINOMA PATIENTS (2013) (0)
Personalized Peptide Vaccination for Castration-Resistant Prostate Cancer Progressing after Docetaxel Chemotherapy: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (2019) (0)
Collaboration of interleukin 2(IL2) and interferonγ (IFNγ) in the induction of human activated killer (AK) cells (1985) (0)
666 A phase-II study of peptide vaccines and dexamethasone versus dexamethasone alone for chemotherapy-naïve castration resistant prostate cancer – a final report (2015) (0)
Establishment and Epitope Analysis of Allo‐Specific Cytotoxic T Lymphocytes at a Tumor Site Recognizing a Spouse's HLA‐A0206 Molecule (2000) (0)
Immune responses of patients without cancer recurrence after a cancer vaccine over a long term (2022) (0)
IgG response against prostate-related antigen as potential biomarker for personalized peptide vaccination in metastatic recurrent breast cancer. (2017) (0)
Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer (2020) (0)
MP-08.07: Immunohistochemical study of the robustness of prostate cancer (2006) (0)
Squamous cell and adeno cancer antigens recognized by cytotoxic T lymphocytes (2003) (0)
Abstract P5-04-21: Analysis of serum immune biomarkers for response to therapeutic personalized peptide vaccination in patients with metastatic breast cancer (2020) (0)
Expressions of human leukocyte antigen-class I, multidrug-resistance 1, and androgen receptor in untreated prostate cancer cells (2007) (0)
Association of PD-L1/CD8+TIL and expression of PD-L1, PTEN as predictive biomarkers for long-term follow-up in early breast cancer. (2017) (0)
A PHASE I TRIAL OF PERSONALISED PEPTIDE VACCINATION FOR CYTOKINE-REFRACTORY METASTATIC RENAL CELL CARCINOMA PATIENTS (2008) (0)
Personalized Peptide Vaccine as a Novel Immunotherapy Against Advanced Cancer (2013) (0)
Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody (1991) (0)
Identification of PeptideVaccine Candidates for Prostate Cancer Patientswith HLA-A 3 (2005) (0)
Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides (2012) (0)
[EA rosette formation]. (1981) (0)
742 Feasibility study of personalized peptide vaccination for platinum-based chemotherapy resistant metastatic upper tract urothelial carcinoma patients (2015) (0)
Detection of guinea pig T mu and T gamma cells by a double rosette assay. (1982) (0)
Lymphocytes of Lung Cancer Protein Recognized by HLA-A 24-restricted Tumor-infiltrating Identification of a New Endoplasmic Reticulum-resident Updated (2000) (0)
Immunologic and clinical effects of personalized selection of peptide vaccines in HLA-A2 positive patients with advanced cancer (2008) (0)
Histocompatibility Leukocyte Antigen‐A2‐restricted and Tumor‐specific Cytotoxic T Lymphocytes from Tumor‐infiltrating Lymphocytes of a Patient with Testicular Embryonal Cancer (1997) (0)
900 OPEN-LABEL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF PERSONALIZED PEPTIDE VACCINATION (PPV) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER(CRPC) (2011) (0)
SART1 Gene Encoding Squamous Cell Carcinoma Antigen Recognized by Cytotoxic T Lymphocytes (2000) (0)
Abstract P4-06-06: Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer (2019) (0)
New Peptide-Based Cancer Vaccine: Phase I and Early Phase II Clinical Trials for Castration-Resistant Prostate Cancer (2012) (0)
WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy (2012) (0)
[Pretreatment and Posttreatment Evaluations of Circulating Tumor Cells（CTC）in Patients with Metastatic Breast Cancer]. (2015) (0)
HETEROGENEITY OF SEVERE COMBINED IMMUNODEFICIENCY DISEASE (SCID); DEMONSTRATION OF PUTATIVE GAMMA CHAIN T CELL RECEPTOR (1987) (0)
Of cyclophilin b derived tumor antigen peptide (1999) (0)
Recognized by the CTL Squamous Cell Carcinoma Antigen Identification of a Gene Coding for a New (2000) (0)
P326 Immunologic and clinical effects of personalized selection of peptide vaccines in patients with refractory breast cancer (2011) (0)
652 A PHASE II STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR ADVANCED UROTHELIAL CARCINOMA PATIENTS WHO FAILED STANDARD TREATMENT (2011) (0)
416: Identification of Parathyroid Hormone-Related Protein-Derived Peptides Immunogenic in Human Histocompatibility Leukocyte Antigen-A24+ Prostate Cancer Patients (2004) (0)
MP2-20 FEASIBILITY STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR PLATINUM-BASED CHEMOTHERAPY RESISTANT METASTATIC UPPER TRACT UROTHELIAL CARCINOMA PATIENTS (2015) (0)
Genes Encoding Antigenic Peptides of Human Epithelial Cancers Recognized by Cytotoxic T Lymphocytes (1999) (0)
604: A Phase I Trial of Vaccination of Personalized Peptides for HLA-A2/A24 Positive Patients with Hormone-Refractory Prostate Cancer (2007) (0)
The QOL of the Hormone-Refractory Prostate Cancer Patients with Clinical Study CTL-precursor Oriented Vaccine (2004) (0)
Immunogenetic analysis of the patients with falciparum malaria in Thailand (1998) (0)
[Cancer vaccine with peptides derived from tumor rejection antigens]. (2001) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kyogo Itoh?

Kyogo Itoh is affiliated with the following schools:

Kyogo Itoh's Academic­Influence.com Rankings

Kyogo Itoh's Degrees

Why Is Kyogo Itoh Influential?

Kyogo Itoh's Published Works

Published Works

What Schools Are Affiliated With Kyogo Itoh?

Kyogo Itoh's AcademicInfluence.com Rankings